BROCHURE

Aiforia Clinical Solutions

For pathology labs looking to increase productivity and improve diagnostic accuracy, Aiforia Clinical Solutions offer AI-supported image-based diagnostics with intelligent visualization, automated screening, and reporting tools in one cloud-based platform. Pathologists can make the most of a digitized workflow and fully harness their expertise by automating repetitive tasks and increasing the speed and accuracy of case reviews.

Only certain Aiforia® Clinical AI models and the Aiforia® Clinical Suite Viewer are CE-IVD marked for diagnostic use in EU and EEA countries, see here for the full list: www.aiforia.com/aiforia-clinical-suite . In all other countries, the use is limited to Research Use Only, not for use in diagnostic procedures.

aiforia®
AI for image analysis

aiforia®

Summary of Features

Tumor Area Detection

Distinguishes between normal and cancerous tissue

Scoring

Automatically scores positive and negative cells from either whole slide images or selected image areas.

Confirm results on WSIs

View images and analysis results in alternate magnifications

Hotspots & ROIs

View image analysis results in selected areas for more precise examination

Creates Heatmap

Automatically finds critical areas of the sample

Mark Images

Add markings and notes to your images to help you share findings with collaborators

Measure

Automatically or manually measure features or patterns of interest.

Report Generation

Results provided in a quantifiable format. Verify results and make adjustments as needed.



Aiforia® Breast Cancer; **Ki67**

The CE-IVD marked AI Model supports the detection of invasive carcinoma and scoring of Ki67 positive and negative tumor cells from whole slide images (WSI) or from selected image areas of cancerous breast tissue.



Clinical Validation

→ Showed excellent correlation with visual diagnosis

→ Improved diagnostic concordance by increasing pathologist agreement

→ Correlated better with survival data compared to visual interpretation

→ Saved Time, especially in the whole slide image scoring (up to 55% faster)

Clinical Performance Values: Ki67 WSI (%)

Sensitivity: 99
Specificity: 85
PPV: 88
NPV: 98

See full Clinical Validation data in Appendix.

Aiforia® Breast Cancer; **ER**

The CE-IVD marked AI Model supports the detection of invasive carcinoma and scoring of ER positive and negative tumor cells from whole slide images (WSI) or from selected image areas of cancerous breast tissue.



Clinical Validation

→ Showed excellent correlation with visual diagnosis

→ The AI-Assisted diagnosis and ER scoring saved time, especially in the whole slide image scoring (up to 37% faster)

Clinical Performance Values: ER WSI (%)

Sensitivity: 98
Specificity: 100
PPV: 100
NPV: 86

See full Clinical Validation data in Appendix.

Aiforia® Breast Cancer; **PR**

The CE-IVD marked AI Model supports the detection of invasive carcinoma and scoring of PR positive and negative tumor cells from whole slide images (WSI) or from selected image areas of cancerous breast tissue.



Clinical Validation

→ Showed excellent correlation with visual diagnosis

→ The AI-Assisted diagnosis and PR scoring produced reductions in average time spent per slide in the WSI analyses (12% faster)

Clinical Performance Values: PR WSI (%)

Sensitivity: 99
Specificity: 94
PPV: 98
NPV: 97

See full Clinical Validation data in Appendix.

Aiforia® Lung Cancer; **PD-L1**



The CE-IVD marked Aiforia® Clinical AI Model for Lung Cancer; PD-L1 is intended for use in non-small cell lung cancer cases and is able to automatically detect the invasive carcinoma areas in these patient samples and then support scoring of the PD-L1 negative and positive tumor cells

Clinical Validation

→ Showed excellent correlation with visual diagnosis

→ Improved diagnostic concordance by increasing pathologist agreement

→ The AI-Assisted Dx and PD-L1 scoring saved time (~22% faster)

Clinical Performance Values: PD-L1 WSI (%)

Sensitivity: 90
Specificity: 97
PPV: 97
NPV: 90

See full Clinical Validation data in Appendix.

Aiforia® Prostate Cancer; **Gleason Grade Groups**

The CE-IVD marked Aiforia® Clinical AI Model for Prostate Cancer supports the detection of adenocarcinoma and assists Gleason grade grouping from the whole slide images (WSI).



Clinical Validation

→ Showed excellent correlation with visual diagnosis

→ The AI-Assisted Gleason scoring produced significant time savings by reducing the time spent per slide by 34%

Clinical Performance Values: Prostate GGG WSI (%)

Sensitivity: 97
Specificity: 90
PPV: 90
NPV: 97

See full Clinical Validation data in Appendix.

aiforia®

The power of AI in your hands

Increased efficiency:

Diagnose more patients in less time by unbinding yourself from time-consuming, manual tasks.

Advanced precision:

Improve diagnostic accuracy and be confident in your decision-making.

Improved consistency:

Reduce variability and bias to standardize your sample review and ensure democratized patient care.

What Makes **Aiforia Unique?**

Future-proof

Together with our clients, we continue to develop new groundbreaking AI models, with thousands of models already developed for research use. We're committed to providing cutting-edge deep-learning AI models designed to meet the evolving needs of our customers. As clinical diagnostics become increasingly complex, our advanced software will ensure clients stay at the forefront of technology.

Ease Of Use

The Aiforia software requires no data scientists or coding expertise. Our team of experts integrates our solutions into existing IT infrastructures. We acknowledge that every lab is different, so we optimize each model for your lab's needs and monitor their performance to deliver continuous improvement. Aiforia's software allows pathologists to confidently scale up their operations while paying only for what they need.

Transparency

Aiforia's AI models are not black boxes. You remain in control, see how analyses are conducted, and participate in the training process. AI models serve as first-read support while the expert verifies the results. We offer a fully automated workflow with quantifiable data and results that can always be adjusted.

Security

We take data privacy and security very seriously. We hold several globally relevant quality and security certifications, so you can be sure your sample and patient data are safe.* You determine what information is stored in the cloud and can opt for a private version.

*Our image analysis solutions are developed and maintained securely per ISO 27001:2013 and SOC 2 Type II security standards, and ISO 13485:2016 quality standards. In addition, we strictly adhere to GDPR requirements and all applicable HIPAA policies and procedures.

Powering clinical diagnostics with future-proof AI

Aiforia provides trusted artificial intelligence solutions that continue to elevate pathologist capabilities and help ensure every patient receives the best possible care.

Only certain Aiforia® Clinical AI models and the Aiforia® Clinical Suite Viewer are CE-IVD marked for diagnostic use in EU and EEA countries, see here for the full list: www.aiforia.com/aiforia-clinical-suite . In all other countries, the use is limited to Research Use Only, not for use in diagnostic procedures.

aiforia®
AI for image analysis

Aiforia Technologies Plc | contact@aiforia.com | www.aiforia.com